Immunohistochemical expression of glucocorticoid and calcitonin receptors as a tool for selecting therapeutic approach in central giant cell granuloma of the jawbones

Clinico-Pathologic Conference AAOMP/IAOP 2008: Case 3

“…This was supported by immunoreactivity of the lesional cells (both mononuclear and multinuclear giant) for corticosteroid receptors [7]. Injections were given over a period of 15 months, during which there were two episodes of recurrence in the mandible and a new focus in the maxilla.…”

Glucocorticoid and calcitonin receptor expression in central giant cell lesions: implications for therapy

“…4 The cellular lineage from which MGCs are derived is controversial. Positive immunohistochemical expression of receptor activator of nuclear factor-kB (RANK), 7 tartrate-resistant acid phosphatase (TRAP), vitronectin receptor (VNR) 2 and calcitonin receptor 8 have suggested an osteoclastic phenotype for MGCs. The presence of CD68 glycoprotein 9 and alpha-1-antichymotrypsin 10 has suggested that MGCs have a macrophage/histiocyte origin.…”

Can calcitonin nasal spray reduce the risk of recurrence of central giant cell granuloma of the jaws? A double-blind clinical trial

“…11 Giant cells have been shown to express osteoclastic markers, such as tartrate-resistant acid phosphatase (TRAP), vitronectin, and CTR, and can resorb lacunar bone in vitro. 13 Aggressive CGCGs have higher CTR expression. Also, Nogueira et al reported no significant difference in CTR expression in the different clinical forms of CGCGs.…”